OBJECTIVE: To investigate opportunities to reduce lung cancer mortality after diagnosis of localised non-small cell lung cancer (NSCLC) in New South Wales through surgical resection. DESIGN, PATIENTS AND SETTING: In this cohort study, resection rates and lung cancer mortality risk were explored using multivariate logistic regression and competing risk regression, respectively. Data for 3040 patients were extracted from the NSW Central Cancer Registry for the diagnostic period 1 January 2003 to 31 December 2007. Subset analyses for patients at low surgical risk indicated resection rates and outcomes under ideal circumstances. MAIN OUTCOME MEASURES: Resection rates and lung cancer mortality. RESULTS: The resection rate in NSW was estimated to...
A best evidence topic in thoracic surgery was written according to a structured protocol. The questi...
BackgroundFor patients with advanced stage non-small cell lung cancer (NSCLC), chemotherapy and chem...
OBJECTIVE:Overall survival (OS) for advanced stage (IIIA-IV) non-small cell lung cancer (NSCLC) is h...
Background: Few patients diagnosed with lung cancer are still alive 5 years after diagnosis. The aim...
Background: Compared with some European countries, England has low lung cancer survival and low use ...
BACKGROUND: Compared with some European countries, England has low lung cancer survival and low use ...
OBJECTIVES: Treatment patterns and outcomes in a population-based database were examined to identify...
Objective: The early and local advanced stages (IA-IIIA) of non-small cell lung cancer (NSCLC) warra...
ObjectiveUsing a national cancer registry, we determined the postoperative survival of patients with...
Lung cancer is the leading cause of cancer death in men and women worldwide. Surgical resection is r...
Objectives: To determine the influence of where a patient is first seen (either surgical or non-surg...
Introduction: The impact of incomplete lung cancer resection on survival has never been systematical...
Introduction:Although lobectomy is considered the standard surgical treatment for stage IA non–small...
Objective: To use linked NSW Cancer Registry and hospital lung cancer (LC) data for raising discussi...
The feasibility of segmental resection for early-stage non-small cell lung cancer (NSCLC) is still c...
A best evidence topic in thoracic surgery was written according to a structured protocol. The questi...
BackgroundFor patients with advanced stage non-small cell lung cancer (NSCLC), chemotherapy and chem...
OBJECTIVE:Overall survival (OS) for advanced stage (IIIA-IV) non-small cell lung cancer (NSCLC) is h...
Background: Few patients diagnosed with lung cancer are still alive 5 years after diagnosis. The aim...
Background: Compared with some European countries, England has low lung cancer survival and low use ...
BACKGROUND: Compared with some European countries, England has low lung cancer survival and low use ...
OBJECTIVES: Treatment patterns and outcomes in a population-based database were examined to identify...
Objective: The early and local advanced stages (IA-IIIA) of non-small cell lung cancer (NSCLC) warra...
ObjectiveUsing a national cancer registry, we determined the postoperative survival of patients with...
Lung cancer is the leading cause of cancer death in men and women worldwide. Surgical resection is r...
Objectives: To determine the influence of where a patient is first seen (either surgical or non-surg...
Introduction: The impact of incomplete lung cancer resection on survival has never been systematical...
Introduction:Although lobectomy is considered the standard surgical treatment for stage IA non–small...
Objective: To use linked NSW Cancer Registry and hospital lung cancer (LC) data for raising discussi...
The feasibility of segmental resection for early-stage non-small cell lung cancer (NSCLC) is still c...
A best evidence topic in thoracic surgery was written according to a structured protocol. The questi...
BackgroundFor patients with advanced stage non-small cell lung cancer (NSCLC), chemotherapy and chem...
OBJECTIVE:Overall survival (OS) for advanced stage (IIIA-IV) non-small cell lung cancer (NSCLC) is h...